AstraZeneca to invest $360 million in new Irish drug manufacturing site By Reuters
[ad_1]

(Reuters) – AstraZeneca (NASDAQ:) said on Tuesday it would invest $360 million to develop an advanced manufacturing facility in Ireland to produce primary ingredients for medicines.
Anglo-Swedish drugmaker has many drugs in development, as well as a wide range of treatments for heart disease and cancer. It purchased Alexion (NASDAQ) in July for $39B.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.
[ad_2]